Heptares Therapeutics Limited

Nxera Pharma UK Limited

Sarah Joanne Aves

Miles Stuart Congreve

Benjamin Gerald Tehan

John Andrew Christopher

Sukhbinder Singh Klair

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

The disclosures herein relate to novel compounds of formula  wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function. 

The disclosures herein relate to novel compounds of formula wherein W, X and Y, Y, Yand Yare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors. 

Orexin receptor antagonists

The disclosures herein relate to novel compounds of formula wherein W, X and Y, Y, Yand Yare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined here, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function. 

The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Growing community of inventors

Cambridge, United Kingdom

Sarah Joanne Aves